Advertisement

Herz

pp 1–9 | Cite as

Management von intrazerebralen Blutungen unter oraler Antikoagulation

  • J. A. Sembill
  • J. B. Kuramatsu
  • S. H. Hohnloser
  • H. B. HuttnerEmail author
Schwerpunkt
  • 66 Downloads

Zusammenfassung

Die Inzidenz der intrazerebralen Blutung (ICB) unter oraler Antikoagulation (OAK) wird mit dem demographischen Wandel weiter zunehmen. Die OAK-ICB ist gekennzeichnet durch größere Blutungsvolumina, häufigere Hämatomprogression und Einbruch in das Ventrikelsystem, woraus insgesamt eine schlechtere Prognose resultiert. Neben dem grundsätzlichen ICB-Akutmanagement ist eine umgehende Gerinnungsnormalisierung anzustreben. Bei ICB unter Vitamin-K-Antagonisten (VKA) sollte so schnell wie möglich eine suffiziente Antagonisierung (Ziel-INR [International Normalized Ratio]: <1,3) durch Prothrombinkomplexkonzentrate (PPSB) mit zusätzlicher Substitution von Vitamin K erfolgen. Bei ICB unter Dabigatran sollte eine umgehende Antagonisierung durch Idarucizumab stattfinden; bei ICB unter Faktor-Xa-Inhibitoren sollte, sobald zugelassen oder im Rahmen klinischer Studien, die Gabe von Andexanet, bei Nichtverfügbarkeit die hochdosierte Gabe von PPSB, erfolgen. Bezüglich des OAK-Wiederbeginns stehen Ergebnisse randomisierter Studien aus. Umfangreiche Beobachtungsstudien und Metaanalysen zeigten unter OAK-Wiederaufnahme eine verringerte Inzidenz thrombembolischer Ereignisse und Mortalität ohne gleichzeitig signifikant vermehrtes Auftreten hämorrhagischer Komplikationen. Die Verwendung von Nicht-Vitamin-K-abhängigen oralen Antikoagulanzien (NOAK) könnte weiter zur Sicherheit der OAK-Wiederaufnahme beitragen, welche bei Vorhofflimmer(VHF)-Patienten nach 4 bis 8 Wochen stattfinden sollte. Demgegenüber ist die VKA-Wiederaufnahme bei Patienten mit mechanischen Herzklappen vor Ablauf einer Woche nach ICB nicht zu empfehlen. Die Sicherheit erscheint weiter durch die ICB-Lokalisation sowie das Vorliegen von zerebralen Mikroblutungen, kortikaler oberflächlicher Siderose und kortikalen/konvexen Subarachnoidalblutungen beeinflusst, weshalb grundsätzlich eine individuelle Risikoabwägung hinsichtlich thrombembolischer versus hämorrhagischer Ereignisse notwendig ist.

Schlüsselwörter

Hirnblutungen Orale Antikoagulation Gerinnungsnormalisierung Vorhofflimmern Mechanische Herzklappe 

Abkürzungen

CAA

Zerebrale Amyloidangiopathie

HR

Hazard-Ratio

ICB

Intrazerebrale Blutung

KI

Konfidenzintervall

NOAK

Nicht-Vitamin-K-abhängige orale Antikoagulanzien

OAK

Orale Antikoagulation

OR

Odds-Ratio

PPSB

Prothrombinkomplexkonzentrat

VHF

Vorhofflimmern

VKA

Vitamin-K-Antagonisten

Management of oral anticoagulation related intracerebral hemorrhage

Abstract

The incidence of intracerebral hemorrhage (ICH) in patients using oral anticoagulation (OAC) will continue to increase with the demographic change of an aging population. As compared to primary spontaneous ICH, OAC-ICH is characterized by larger hematoma volumes, more frequent hematoma enlargement and intraventricular hemorrhage resulting in an even worse prognosis. Specific treatment should focus on immediate reversal of anticoagulation in addition to the basic acute management of ICH. In ICH patients using vitamin K antagonists (VKA), complete anticoagulant reversal with an international normalized ratio (INR) <1.3 should be achieved as quickly as possible using prothrombin complex concentrate (PCC) with additional substitution of vitamin K. Patients with ICH under dabigatran treatment should receive idarucizumab. In ICH patients using factor-Xa inhibitors, andexanet should be administered as soon as approved in Europe or within clinical studies and if unavailable alternatively high-dose PCC administration. Regarding OAC resumption, results from randomized trials are pending. In comprehensive observational studies and meta-analyses ICH patients resuming OAC showed a reduced incidence of thromboembolic events and mortality without significantly increased rates of hemorrhagic complications. Non-vitamin K dependent oral anticoagulants (NOAC) might further increase the safety of OAC resumption, which should be initiated after 4–8 weeks for patients with atrial fibrillation. In contrast, VKA resumption in patients with mechanical heart valves should not take place earlier than 1 week after ICH. Generally, safety of OAC resumption appears to be affected by ICH localization along with the presence of cerebral microbleeding, cortical superficial siderosis and cortical/convexity subarachnoid hemorrhage, making it crucial to weigh up the individual patient risk with respect to thromboembolic versus hemorrhagic events.

Keywords

Intracranial hemorrhages Oral anticoagulation Anticoagulant reversal Atrial fibrillation Mechanical heart valves 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J.A. Sembill, J.B. Kuramatsu, S.H. Hohnloser und H.B. Huttner geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Hemphill JC 3rd, Greenberg SM, Anderson CS et al (2015) Heart 46(7):2032–2060.  https://doi.org/10.1161/str.0000000000000069 CrossRefGoogle Scholar
  2. 2.
    Schols AM, Schreuder FH, van Raak EP et al (2014) Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke 45(1):268–270.  https://doi.org/10.1161/STROKEAHA.113.003003 CrossRefPubMedGoogle Scholar
  3. 3.
    Kuramatsu JB et al (2015) Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313(8):824–836.  https://doi.org/10.1001/jama.2015.0846 CrossRefPubMedGoogle Scholar
  4. 4.
    van Asch CJ, Luitse MJ, Rinkel GJ et al (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 9(2):167–176.  https://doi.org/10.1016/s1474-4422(09)70340-0 CrossRefPubMedGoogle Scholar
  5. 5.
    Sacco S, Marini C, Toni D et al (2009) Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 40(2):394–399.  https://doi.org/10.1161/STROKEAHA.108.523209 CrossRefPubMedGoogle Scholar
  6. 6.
    Qureshi AI, Mendelow AD, Hanley DF (2009) Intracerebral haemorrhage. Lancet 373(9675):1632–1644.  https://doi.org/10.1016/s0140-6736(09)60371-8 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fabritz L, Guasch E, Antoniades C et al (2016) Expert consensus document: defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol 13(4):230–237.  https://doi.org/10.1038/nrcardio.2015.194 CrossRefPubMedGoogle Scholar
  8. 8.
    Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 26(8):1471–1477CrossRefGoogle Scholar
  9. 9.
    Biffi A et al (2011) Warfarin-related intraventricular hemorrhage: imaging and outcome. Baillieres Clin Neurol 77(20):1840–1846.  https://doi.org/10.1212/WNL.0b013e3182377e12 CrossRefGoogle Scholar
  10. 10.
    Flibotte JJ et al (2004) Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Baillieres Clin Neurol 63(6):1059–1064Google Scholar
  11. 11.
    Boulouis G et al (2017) Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry 88(4):339–345.  https://doi.org/10.1136/jnnp-2016-315346 CrossRefPubMedGoogle Scholar
  12. 12.
    Brouwers HB, Chang Y, Falcone GJ et al (2014) Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol 71(2):158–164.  https://doi.org/10.1001/jamaneurol.2013.5433 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kuramatsu JB, Sembill JA, Gerner ST et al (2018) Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J.  https://doi.org/10.1093/eurheartj/ehy056 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Steiner T, Poli S, Griebe M et al (2016) Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 15(6):566–573.  https://doi.org/10.1016/S1474-4422(16)00110-1 CrossRefPubMedGoogle Scholar
  15. 15.
    Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ (2013) New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 70(12):1486–1490.  https://doi.org/10.1001/jamaneurol.2013.4021 CrossRefPubMedGoogle Scholar
  16. 16.
    Inohara T et al (2018) Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA 319(5):463–473.  https://doi.org/10.1001/jama.2017.21917 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gerner ST et al (2018) Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 83(1):186–196.  https://doi.org/10.1002/ana.25134 CrossRefPubMedGoogle Scholar
  18. 18.
    Hawryluk GW, Austin JW, Furlan JC et al (2010) Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemostasis 8(7):1500–1508.  https://doi.org/10.1111/j.1538-7836.2010.03882.x CrossRefGoogle Scholar
  19. 19.
    Tsivgoulis G, Lioutas VA, Varelas P et al (2017) Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage. Baillieres Clin Neurol 89(11):1142–1151.  https://doi.org/10.1212/WNL.0000000000004362 CrossRefGoogle Scholar
  20. 20.
    Kurogi R, Nishimura K, Nakai M et al (2018) Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Baillieres Clin Neurol 90(13):e1143–e1149.  https://doi.org/10.1212/WNL.0000000000005207 CrossRefGoogle Scholar
  21. 21.
    Ebner M, Birschmann I, Peter A et al (2017) Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care 21(1):32.  https://doi.org/10.1186/s13054-017-1619-z CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Pollack CV Jr., Reilly PA, van Ryn J et al (2017) Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 377(5):431–441.  https://doi.org/10.1056/NEJMoa1707278 CrossRefPubMedGoogle Scholar
  23. 23.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151.  https://doi.org/10.1056/NEJMoa0905561 CrossRefPubMedGoogle Scholar
  24. 24.
    Sembill JA et al (2018) Impact of recent studies for the treatment of Intracerebral hemorrhage. Curr Neurol Neurosci Rep 18(10):71.  https://doi.org/10.1007/s11910-018-0872-0 CrossRefPubMedGoogle Scholar
  25. 25.
    Connolly SJ, Milling TJ Jr., Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med.  https://doi.org/10.1056/NEJMoa1607887 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373(25):2413–2424.  https://doi.org/10.1056/NEJMoa1510991 CrossRefPubMedGoogle Scholar
  27. 27.
    Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57(2):173–180.  https://doi.org/10.1016/j.jacc.2010.09.024 CrossRefPubMedGoogle Scholar
  28. 28.
    Gage BF, van Walraven C, Pearce L et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110(16):2287–2292.  https://doi.org/10.1161/01.CIR.0000145172.55640.93 CrossRefPubMedGoogle Scholar
  29. 29.
    Biffi A et al (2015) Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 314(9):904–912.  https://doi.org/10.1001/jama.2015.10082 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Steiner T, Al-Shahi Salman R, Beer R et al (2014) European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 9(7):840–855.  https://doi.org/10.1111/ijs.12309 CrossRefPubMedGoogle Scholar
  31. 31.
    Majeed A, Kim YK, Roberts RS et al (2010) Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 41(12):2860–2866.  https://doi.org/10.1161/STROKEAHA.110.593087 CrossRefPubMedGoogle Scholar
  32. 32.
    Yung D et al (2012) Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol 28(1):33–39. https://doi.org/10.1016/j.cjca .2011.10.002 S0828-282X(11)01310-9CrossRefGoogle Scholar
  33. 33.
    Poli D, Antonucci E, Dentali F et al (2014) Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Baillieres Clin Neurol 82(12):1020–1026.  https://doi.org/10.1212/WNL.0000000000000245 CrossRefGoogle Scholar
  34. 34.
    Nielsen PB, Larsen TB, Skjoth F et al (2015) Restarting anticoagulant treatment after Intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132(6):517–525.  https://doi.org/10.1161/CIRCULATIONAHA.115.015735 CrossRefPubMedGoogle Scholar
  35. 35.
    Ottosen TP, Grijota M, Hansen ML et al (2016) Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke 47(7):1837–1843.  https://doi.org/10.1161/STROKEAHA.116.012945 CrossRefPubMedGoogle Scholar
  36. 36.
    Park YA, Uhm JS, Pak HN et al (2016) Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm 13(9):1794–1802.  https://doi.org/10.1016/j.hrthm.2016.05.016 CrossRefPubMedGoogle Scholar
  37. 37.
    Vestergaard AS, Skjoth F, Lip GY, Larsen TB (2016) Effect of anticoagulation on hospitalization costs after intracranial hemorrhage in atrial fibrillation: a registry study. Stroke 47(4):979–985.  https://doi.org/10.1161/STROKEAHA.115.012338 CrossRefPubMedGoogle Scholar
  38. 38.
    Pennlert J, Overholser R, Asplund K et al (2017) Optimal timing of anticoagulant treatment after Intracerebral hemorrhage in patients with atrial fibrillation. Stroke 48(2):314–320.  https://doi.org/10.1161/STROKEAHA.116.014643 CrossRefPubMedGoogle Scholar
  39. 39.
    Chao TF, Liu CJ, Liao JN et al (2016) Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of Intracranial hemorrhage. Circulation 133(16):1540–1547.  https://doi.org/10.1161/CIRCULATIONAHA.115.019794 CrossRefPubMedGoogle Scholar
  40. 40.
    Korompoki E, Filippidis FT, Nielsen PB et al (2017) Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 89(7):687–696.  https://doi.org/10.1212/WNL.0000000000004235 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Murthy SB, Gupta A, Merkler AE et al (2017) Restarting anticoagulant therapy after Intracranial hemorrhage: a systematic review and meta-analysis. Stroke 48(6):1594–1600.  https://doi.org/10.1161/STROKEAHA.116.016327 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Chai-Adisaksopha C et al (2017) Warfarin resumption following anticoagulant-associated intracranial hemorrhage: a systematic review and meta-analysis. Thromb Res 160:97–104.  https://doi.org/10.1016/j.thromres.2017.11.001 CrossRefPubMedGoogle Scholar
  43. 43.
    Zhou Z, Yu J, Carcel C et al (2018) Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open 8(5):e19672.  https://doi.org/10.1136/bmjopen-2017-019672 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Biffi A, Kuramatsu JB, Leasure A et al (2017) Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol 82(5):755–765.  https://doi.org/10.1002/ana.25079 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sembill JA, Wieser CY, Sprugel MI et al (2018) Initiating anticoagulant therapy after ICH is associated with patient characteristics and treatment recommendations. J Neurol 265(10):2404–2414.  https://doi.org/10.1007/s00415-018-9009-2 CrossRefPubMedGoogle Scholar
  46. 46.
    Sembill JA et al (2017) Severity assessment in maximally treated ICH patients: the max-ICH score. Baillieres Clin Neurol 89(5):423–431.  https://doi.org/10.1212/WNL.0000000000004174 CrossRefGoogle Scholar
  47. 47.
    Katsanos AH, Schellinger PD, Kohrmann M et al (2018) Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis. Eur J Neurol 25(10):1299–1302.  https://doi.org/10.1111/ene.13742 CrossRefPubMedGoogle Scholar
  48. 48.
    Wolfe Z et al (2018) A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost 16(7):1296–1306.  https://doi.org/10.1111/jth.14131 CrossRefPubMedGoogle Scholar
  49. 49.
    Eikelboom JW, Wallentin L, Connolly SJ et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123(21):2363–2372.  https://doi.org/10.1161/circulationaha.110.004747 CrossRefPubMedGoogle Scholar
  50. 50.
    Vahanian A, Iung B (2012) The new ESC/EACTS guidelines on the management of valvular heart disease. Arch Cardiovasc Dis 105(10):465–467.  https://doi.org/10.1016/j.acvd.2012.09.001S1875-2136(12)00243-4 CrossRefPubMedGoogle Scholar
  51. 51.
    Nishimura RA et al (2017) 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 70(2):252–289.  https://doi.org/10.1016/j.jacc.2017.03.011 CrossRefPubMedGoogle Scholar
  52. 52.
    Halvorsen S, Storey RF, Rocca B et al (2017) Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 38(19):1455–1462.  https://doi.org/10.1093/eurheartj/ehw454 CrossRefPubMedGoogle Scholar
  53. 53.
    Rodrigues MA, Samarasekera N, Lerpiniere C et al (2018) The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol 17(3):232–240.  https://doi.org/10.1016/S1474-4422(18)30006-1 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Linn J, Halpin A, Demaerel P et al (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 74(17):1346–1350.  https://doi.org/10.1212/WNL.0b013e3181dad60574/17/1346 CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    van Etten ES, Gurol ME, van der Grond J et al (2016) Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 87(14):1482–1487.  https://doi.org/10.1212/WNL.0000000000003181 CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Charidimou A, Imaizumi T, Moulin S et al (2017) Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis. Neurology 89(8):820–829.  https://doi.org/10.1212/WNL.0000000000004259 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Charidimou A et al (2017) Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF. Neurology 89(23):2317–2326.  https://doi.org/10.1212/WNL.0000000000004704 CrossRefPubMedGoogle Scholar
  58. 58.
    Roongpiboonsopit D et al (2016) Cortical superficial siderosis predicts early recurrent lobar hemorrhage. Neurology 87(18):1863–1870.  https://doi.org/10.1212/wnl.0000000000003281 CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Holmes DR, Reddy VY, Turi ZG et al (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374(9689):534–542.  https://doi.org/10.1016/S0140-6736(09)61343-X CrossRefPubMedGoogle Scholar
  60. 60.
    Holmes DR Jr., Kar S, Price MJ et al (2014) Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64(1):1–12.  https://doi.org/10.1016/j.jacc.2014.04.029 CrossRefPubMedGoogle Scholar
  61. 61.
    Holmes DR Jr S et al (2015) Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65(24):2614–2623CrossRefGoogle Scholar
  62. 62.
    Piccini JP, Sievert H, Patel MR (2017) Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. Eur Heart J 38(12):869–876.  https://doi.org/10.1093/eurheartj/ehw330 CrossRefPubMedGoogle Scholar
  63. 63.
    Reddy VY, Mobius-Winkler S, Miller MA et al (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 61(25):2551–2556.  https://doi.org/10.1016/j.jacc.2013.03.035S0735-1097(13)01415-0 CrossRefPubMedGoogle Scholar
  64. 64.
    Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J.  https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Nielsen-Kudsk JE et al (2017) Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention 13(3):371–378.  https://doi.org/10.4244/EIJ-D-17-00201 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • J. A. Sembill
    • 1
  • J. B. Kuramatsu
    • 1
  • S. H. Hohnloser
    • 2
  • H. B. Huttner
    • 1
    Email author
  1. 1.Klinik für NeurologieUniversitätsklinikum ErlangenErlangenDeutschland
  2. 2.Klinik für Kardiologie, Abt. Klinische ElektrophysiologieUniversitätsklinikum FrankfurtFrankfurt am MainDeutschland

Personalised recommendations